MASLD overtakes global liver health as silent epidemic grows

Metabolic dysfunction-associated steatotic liver disease, or MASLD, is now the most common chronic liver condition globally. The name was updated in 2023 to replace the older term nonalcoholic fatty liver disease—a shift aimed at clarifying its metabolic causes and reducing stigma associated with the condition. MASLD develops when excess fat accumulates in the liver, often linked to metabolic issues like obesity or type 2 diabetes. It affects roughly one in three people worldwide, though precise global figures for 2023 remain unclear.

Early signs of the disease can be subtle and easily missed. Some may notice increased thirst, poor sleep, or brain fog, while others experience fatigue or mild abdominal discomfort. Blood tests showing slightly raised liver enzymes or imaging revealing an enlarged liver can also point to MASLD. If left untreated, the condition may advance to metabolic dysfunction-associated steatohepatitis (MASH), where inflammation and liver damage occur. However, early detection through regular check-ups can halt progression and, in some cases, even reverse the damage.

MASLD remains a widespread but often overlooked health issue. Recognising its early symptoms and metabolic triggers allows for timely intervention. With proper management, many cases can be improved or resolved before serious complications develop.